Download fulltext HTML
Nikfarjam, E., Eftekhar, M., Fatehi, H., & Arabian, S. (2024). Letrozole and ovarian hyperstimulation syndrome: Retrospective cross-sectional study. International Journal of Reproductive BioMedicine (IJRM), 22(3), 211–218. https://doi.org/10.18502/ijrm.v22i3.16165

https://doi.org/10.18502/ijrm.v22i3.16165

statistics

  • 117 Abstract Views
  • 77 PDF Views
  • 0 HTML Views

authors

  • Elham Nikfarjam

    Elham Nikfarjam

    Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Maryam Eftekhar

    Maryam Eftekhar

    Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Hanieh Fatehi

    Hanieh Fatehi

    Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Sahereh Arabian

    Sahereh Arabian

    Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Published Date

  • May 12, 2024

Letrozole and ovarian hyperstimulation syndrome: Retrospective cross-sectional study

International Journal of Reproductive BioMedicine (IJRM) / International Journal of Reproductive BioMedicine (IJRM): Volume 22, Issue No. 3 / Pages 211–218

Abstract

Background: Recently, letrozole has been used to prevent moderate to severe ovarian hyperstimulation syndrome (OHSS) in assisted reproductive technology cycles due to its estrogen-reducing and androgen-increasing effects on the ovaries, affecting granulosa cells, and reducing vascular endothelial growth factor production.


Objective: This study aimed to investigate the impact of letrozole consumption in preventing OHSS in infertile women with polycystic ovarian syndrome undergoing in vitro fertilization.


Materials and Methods: In this cross-sectional study, among 1743 medical records of infertile women who were scheduled for oocyte retrieval at Research and Clinical Center for Infertility, Yazd, Iran. Data of 343 women with polycystic ovarian syndrome diagnosis and at risk of OHSS was extracted from March 2022–2023. The stimulation was carried out using a flexible gonadotropin releasing hormone (GnRH) antagonist protocol. Women were divided into 2 groups based on whether they received letrozole or not. In the letrozole group, 2.5 mg letrozole twice daily was continued from the trigger day, while in the control group, women did not receive letrozole. The parameters of OHSS severity, hospitalization rates, and the need for albumin prescription were analyzed.


Results: 89 women in the letrozole and 254 women in the control group were examined. There was no statistically significant difference between groups in terms of age and body mass index; however, anti-Mullerian hormone was significantly higher than control group (7.53 ± 4.61 vs. 5.47 ± 3.63, p < 0.001). The parameters of OHSS severity, hospitalization rates, and the need for albumin prescription showed no significant differences between the groups.


Conclusion: Recent study indicates that incorporating letrozole into the treatment of GnRH antagonists and cabergoline does not reduce the OHSS severity.


Key words: Letrozole, Polycystic ovary syndrome, Ovarian hyperstimulation syndrome, Assisted reproductive technologies.

References
[1] Du D-F, Li M-F, Li X-L. Ovarian hyperstimulation syndrome: A clinical retrospective study on 565 inpatients. Gynecol Endocrinol 2020; 36: 313–317.

[2] Palomba S, Costanzi F, Nelson SM, Caserta D, Humaidan P. Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: A systematic umbrella review of the best clinical evidence. Reprod Biol Endocrinol 2023; 21: 67.

[3] Choudhary RA, Vora PH, Darade KK, Pandey S, Ganla KN. A prospective randomised comparative clinical trial study of luteal phase letrozole versus ganirelix acetate administration to prevent severity of early onset OHSS in ARTs. Int J Fertil Steril 2021; 15: 263–268.

[4] Di Guardo F, Lello Ch, Incognito GG, Bruno MT, Palumbo M. Letrozole and ovarian hyperstimulation syndrome (OHSS): A promising prevention strategy. J Clin Med 2023; 12: 614.

[5] Namvar Jahromi B, Parsanezhad ME, Shomali Z, Bakhshai P, Alborzi M, Moin Vaziri N, et al. Ovarian hyperstimulation syndrome: A narrative review of its pathophysiology, risk factors, prevention, classification, and management. Iran J Med Sci 2018; 43: 248–260.

[6] Pellicer N, Pellicer A. Pathogenesis and management in OHSS. Dahan MH, Fatemi HM, Polyzos NP, Garcia- Velasco JA. Handbook of current and novel protocols for the treatment of infertility. UK: Academic Press, Elsevier; 2024.

[7] El-Khayat W, Elsadek M. Calcium infusion for the prevention of ovarian hyperstimulation syndrome: A double-blind randomized controlled trial. Fertil Steril 2015; 103: 101–105.

[8] Zhang Q, Ma Y, Bu X, Jia C, Liu Y, Wang S. Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome. Int J Gynecol Obstet 2022; 159: 944–950.

[9] Zhao J, Xu B, Huang X, Yan Y, Li Y. Whether letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis. Reprod Health 2020; 17: 181.

[10] Attalla W, Abd Elhamidb T. Aromatase inhibitors versus cabergoline for the prevention of ovarian hyperstimulation syndrome: A prospective, randomized, double-blind study. Evid Based Women’s Health J 2017; 7: 22–29.

[11] Agarwal S, Krishna D, Rao KA. Prevention and management of ovarian hyperstimulation syndrome. Int J Infertil Fetal Med 2019; 10: 46–51.

[12] Minami T, Yamana H, Shigemi D, Matsui H, Fushimi K, Yasunaga H. Artificial colloids versus human albumin for the treatment of ovarian hyperstimulation syndrome: A retrospective cohort study. Int J Reprod BioMed 2019; 17: 709.

[13] Fouda UM, Elshaer HS, Youssef GG, Hanafy A, Mehrem WM, Youssef MA, et al. Cabergoline versus calcium infusion in the prevention of ovarian hyperstimulation syndrome: A randomised controlled study. J Obstet Gynaecol 2022; 42: 122–126.

[14] Mohammadi Yeganeh L, Moini A, Shiva M, Mirghavam N, Bagheri Lankarani N. Methylprednisolone for prevention of ovarian hyperstimulation syndrome in patients with polycystic ovarian syndrome undergoing in-vitro fertilisation: A randomised controlled trial. J Obstet Gynaecol 2018; 38: 241–246.

[15] Eftekhar M, Saeed L. Effect of adding letrozole to gonadotropin on in vitro fertilization outcomes: An RCT. Int J Reprod BioMed 2020; 18: 287–294.

[16] Mangal S. Current knowledge on the use of letrozole in ovarian stimulation. Int J Infertil Fetal Med 2021; 11: 48– 53.

[17] Qi Q, Xia Y, Luo J, Wang Y, Xie Q. Cocktail treatment by GnRH-antagonist, letrozole, and mifepristone for the prevention of ovarian hyperstimulation syndrome: A prospective randomized trial. Gynecol Endocrinol 2023; 39: 2269281.

[18] Chen Y, Yang T, Hao C, Zhao J. A retrospective study of letrozole treatment prior to human chorionic gonadotropin in women with polycystic ovary syndrome undergoing in vitro fertilization at risk of ovarian hyperstimulation syndrome. Med Sci Monit 2018; 24: 4248–4253.

[19] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19–25.

[20] Yanagihara Y, Tanaka A, Nagayoshi M, Tanaka I, Ohno M, Itakura A. Combined use of letrozole, cabergoline and GnRH antagonist eliminates ovarian hyperstimulation syndrome (OHSS) in polycystic ovarian syndrome (PCOS). Evid Based Women’s Health J 2022; 12: 262–269.

[21] Ghasemi Tehrani H, Aasasi K, Mardanian F, Mehrabian F, Movahedi M, Naghshineh E. Evaluation of the effect of letrozole in the ovarian hyperstimulation syndrome prevention in participants at risk of treatment with ovulation-stimulating drugs: A randomized controlled trial. Rep Biochem Mol Biol 2022; 11: 386–393.